Drug Trial Radar · NCT07749157
A Study of Subcutaneously Administered RO7845860 in Participants With Relapsing Multiple Sclerosis
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
85
Planned (sponsor's estimate)
Start
Dec 14, 2026
Primary completion
Feb 28, 2031
Study completion Dec 28, 2031
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Aug 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and, pharmacodynamics (PD) of subcutaneously administered RO7845860 in participants with relapsing multiple sclerosis (RMS).
Conditions
- Relapsing Multiple Sclerosis
Interventions
RO7845860Drug
Participants will receive RO7845860 as an subcutaneous (SC) injection per the schedule in the protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1, 2 and 3: Incidence and Severity of Adverse Events (AEs)Time frame: From Baseline up to approximately Week 96
- Part 1, 2 and 3: Change From Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: From Baseline up to approximately Week 96
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.